The Medicines and Healthcare products Regulatory Agency (MHRA)—regulatory body of the United Kingdom—has awarded an ‘Innovation Passport’ to CellResearch, a Singaporean biotech, for CorLiCyte—an umbilical cord lining stem cell therapy.
CorLiCyte has been awarded the Innovation Passport through MHRA’s Innovation Licensing and Access Pathway (ILAP) for the treatment of chronic diabetic foot ulcers (DFUs), which affects more than 30 million people worldwide. The award is expected to facilitate accelerated access to the stem cell therapy for patients suffering from DFUs in the UK.
